$107.55 Million in Sales Expected for Inogen Inc (NASDAQ:INGN) This Quarter

Wall Street brokerages forecast that Inogen Inc (NASDAQ:INGN) will announce sales of $107.55 million for the current fiscal quarter, Zacks Investment Research reports. Six analysts have provided estimates for Inogen’s earnings, with estimates ranging from $104.10 million to $110.68 million. Inogen posted sales of $97.24 million in the same quarter last year, which suggests a positive year over year growth rate of 10.6%. The business is expected to report its next earnings results on Tuesday, August 6th.

On average, analysts expect that Inogen will report full-year sales of $409.24 million for the current financial year, with estimates ranging from $407.57 million to $411.30 million. For the next financial year, analysts expect that the firm will post sales of $470.86 million, with estimates ranging from $458.56 million to $482.90 million. Zacks’ sales averages are a mean average based on a survey of sell-side research firms that that provide coverage for Inogen.

Inogen (NASDAQ:INGN) last posted its quarterly earnings data on Tuesday, May 7th. The medical technology company reported $0.24 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.29 by ($0.05). The firm had revenue of $90.20 million for the quarter, compared to analysts’ expectations of $89.69 million. Inogen had a net margin of 12.56% and a return on equity of 15.59%. The company’s revenue for the quarter was up 14.1% on a year-over-year basis. During the same quarter in the prior year, the business earned $0.48 EPS.

INGN has been the topic of a number of analyst reports. Zacks Investment Research lowered shares of Inogen from a “buy” rating to a “hold” rating in a research note on Thursday, February 14th. Needham & Company LLC reiterated a “strong-buy” rating and set a $191.00 price objective (down previously from $280.00) on shares of Inogen in a research note on Wednesday, February 27th. ValuEngine lowered shares of Inogen from a “hold” rating to a “sell” rating in a research note on Thursday, February 28th. BidaskClub lowered shares of Inogen from a “hold” rating to a “sell” rating in a research note on Wednesday, March 6th. Finally, JPMorgan Chase & Co. lowered shares of Inogen from an “overweight” rating to a “neutral” rating and dropped their price objective for the company from $175.00 to $72.00 in a research note on Wednesday, May 8th. Two analysts have rated the stock with a sell rating, two have assigned a hold rating, two have assigned a buy rating and one has given a strong buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and a consensus price target of $121.60.

INGN opened at $67.39 on Thursday. The company has a market cap of $1.45 billion, a PE ratio of 29.30, a PEG ratio of 2.61 and a beta of 1.58. Inogen has a 52-week low of $62.31 and a 52-week high of $287.79. The company has a debt-to-equity ratio of 0.02, a quick ratio of 6.70 and a current ratio of 7.35.

Several large investors have recently modified their holdings of the stock. BlackRock Inc. increased its stake in shares of Inogen by 3.3% in the first quarter. BlackRock Inc. now owns 2,305,961 shares of the medical technology company’s stock worth $219,919,000 after buying an additional 72,658 shares during the last quarter. William Blair Investment Management LLC increased its stake in shares of Inogen by 62.2% in the first quarter. William Blair Investment Management LLC now owns 1,048,413 shares of the medical technology company’s stock worth $99,987,000 after buying an additional 402,150 shares during the last quarter. Janus Henderson Group PLC increased its stake in shares of Inogen by 15,943.5% in the first quarter. Janus Henderson Group PLC now owns 552,056 shares of the medical technology company’s stock worth $52,650,000 after buying an additional 548,615 shares during the last quarter. Norges Bank bought a new stake in shares of Inogen in the fourth quarter worth $48,104,000. Finally, New York State Common Retirement Fund increased its stake in shares of Inogen by 19.7% in the first quarter. New York State Common Retirement Fund now owns 368,575 shares of the medical technology company’s stock worth $35,151,000 after buying an additional 60,701 shares during the last quarter. Institutional investors and hedge funds own 98.63% of the company’s stock.

Inogen Company Profile

Inogen, Inc, a medical technology company, primarily develops, manufactures, and markets portable oxygen concentrators for patients, physicians and other clinicians, and third-party payors in the United States and internationally. Its oxygen concentrators are used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions.

Further Reading: What is a blue-chip stock?

Get a free copy of the Zacks research report on Inogen (INGN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Inogen (NASDAQ:INGN)

Receive News & Ratings for Inogen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inogen and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply